Hamburg - The law firm NEUWERK has advised the University of Cologne on the conclusion of a collaboration and licensing agreement for the joint development and commercialization of a SARS-CoV2 neutralizing antibody with the Philipps University of Marburg and the pharmaceutical company Boehringer Ingelheim.
With the agreement, the parties aim to combine their expertise to better treat and prevent COVID-19 in the future. Just before Christmas 2020, the parties announced the start of a Phase 1/2a clinical trial of a new SARS-CoV-2 neutralizing antibody. The new antibody was isolated from the blood of recovered COVID-19 patients at the University Hospital of Cologne. The neutralizing activity against SARS-CoV-2 was investigated at the University of Marburg and the antibody was further developed in collaboration with Boehringer Ingelheim. Boehringer Ingelheim manufactures the antibodies for clinical trials.
NEUWERK advised the University of Cologne on all legal aspects of the collaboration, including proposed royalty and milestone payments and financing of the research and development activities.
Advisors for the University of Cologne: NEUWERK, Hamburg Börge Seeger, MLE, JSM, CLP (transaction lead, partner) Dr. Jonas Welge (Associate)
About NEUWERK: NEUWERK was founded in 2016 by lawyers from Freshfields Bruckhaus Deringer and ROXIN in Hamburg. NEUWERK brings together specialists from the fields of labor law, corporate law/M&A, IP/IT, real estate law, litigation and white-collar criminal law/criminal compliance.
Press contact: For further questions please contact Dr. Sebastian Naber (email@example.com), T +49 40 340 5757-30.
NEUWERK Rechtsanwälte PartG mbB, Gänsemarkt 35, 20354 Hamburg, Germany www.neuwerk.legal